Multiple molecular and cellular mechanisms of the antitumour effect of dihydromyricetin (Review)
- Authors:
- Tian Xia
- Runzhi Zhu
-
Affiliations: National Clinical Research Center for Child Health, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310052, P.R. China - Published online on: March 26, 2024 https://doi.org/10.3892/br.2024.1769
- Article Number: 82
-
Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Mullard A: Addressing cancer's grand challenges. Nat Rev Drug Discov. 19:825–826. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Kashyap D, Tuli HS, Yerer MB, Sharma A, Sak K, Srivastava S, Pandey A, Garg VK, Sethi G and Bishayee A: Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Semin Cancer Biol. 69:5–23. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chang L, Ruiz P, Ito T and Sellers WR: Targeting pan-essential genes in cancer: Challenges and opportunities. Cancer Cell. 39:466–479. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Shafabakhsh R and Asemi Z: Quercetin: A natural compound for ovarian cancer treatment. J Ovarian Res. 12(55)2019.PubMed/NCBI View Article : Google Scholar | |
|
Kim C and Kim B: Anti-Cancer natural products and their bioactive compounds inducing ER stress-mediated apoptosis: A review. Nutrients. 10(1021)2018.PubMed/NCBI View Article : Google Scholar | |
|
Demain AL and Vaishnav P: Natural products for cancer chemotherapy. Microb Biotechnol. 4:687–699. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Zuo W and Kwok HF: Development of marine-derived compounds for cancer therapy. Mar Drugs. 19(342)2021.PubMed/NCBI View Article : Google Scholar | |
|
Sun CC, Li Y, Yin ZP and Zhang QF: Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability. J Sci Food Agric. 101:3862–3869. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wu J, Xiao Z, Li H, Zhu N, Gu J, Wang W, Liu C, Wang W and Qin L: Present status, challenges, and prospects of dihydromyricetin in the battle against cancer. Cancers (Basel). 14(3487)2022.PubMed/NCBI View Article : Google Scholar | |
|
Sun Y, Liu S, Yang S, Chen C, Yang Y, Lin M, Liu C, Wang W, Zhou X, Ai Q, et al: Mechanism of dihydromyricetin on inflammatory diseases. Front Pharmacol. 12(794563)2022.PubMed/NCBI View Article : Google Scholar | |
|
Cheng P, Gui C, Huang J, Xia Y, Fang Y, Da G and Zhang X: Molecular mechanisms of ampelopsin from Ampelopsis megalophylla induces apoptosis in HeLa cells. Oncol Lett. 14:2691–2698. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Chen L, Shi M, Lv C, Song Y, Wu Y, Liu S, Zheng Z, Lu X and Qin S: Dihydromyricetin acts as a potential redox balance mediator in cancer chemoprevention. Mediators Inflamm. 2021(6692579)2021.PubMed/NCBI View Article : Google Scholar | |
|
Sun J, Wang Y, Tang W and Gong J: Enantioselectivity of chiral dihydromyricetin in multicomponent solid solutions regulated by subtle structural mutation. IUCrJ. 10(Pt 2):164–176. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Geng S, Yuan Y, Jiang X, Zhang R, Ma H, Liang G and Liu B: An investigation on pickering nano-emulsions stabilized by dihydromyricetin/high-amylose corn starch composite particles: Preparation conditions and carrier properties. Curr Res Food Sci. 6(100458)2023.PubMed/NCBI View Article : Google Scholar | |
|
Lyu Q, Chen L, Lin S, Cao H and Teng H: A designed self-microemulsion delivery system for dihydromyricetin and its dietary intervention effect on high-fat-diet fed mice. Food Chem. 390(132954)2022.PubMed/NCBI View Article : Google Scholar | |
|
Ye J, Bao S, Zhao S, Zhu Y, Ren Q, Li R, Xu X and Zhang Q: Self-Assembled micelles improve the oral bioavailability of dihydromyricetin and anti-acute alcoholism activity. AAPS PharmSciTech. 22(111)2021.PubMed/NCBI View Article : Google Scholar | |
|
Liu L, Li Y, Zhang M, Zhang Y and Lou B: A Drug-Drug cocrystal of dihydromyricetin and pentoxifylline. J Pharm Sci. 111:82–87. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Sun Z, Lu W, Lin N, Lin H, Zhang J, Ni T, Meng L, Zhang C and Guo H: Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1. Biochem Pharmacol. 175(113888)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wei C, Chen X, Chen D, Yu B, Zheng P, He J, Chen H, Yan H, Luo Y and Huang Z: Dihydromyricetin enhances intestinal antioxidant capacity of growing-finishing pigs by activating ERK/Nrf2/HO-1 signaling pathway. Antioxidants (Basel). 11(704)2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhou J, Hou P, Yao Y, Yue J, Zhang Q, Yi L and Mi M: Dihydromyricetin improves high-fat diet-induced hyperglycemia through ILC3 Activation via a SIRT3-Dependent Mechanism. Mol Nutr Food Res. 66(e2101093)2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhang ZY, Liu C, Wang PX, Han YW, Zhang YW, Hao ML, Song ZX and Zhang XY: Dihydromyricetin Alleviates H9C2 cell apoptosis and autophagy by regulating CircHIPK3 Expression and PI3K/AKT/mTOR pathway. Chin J Integr Med. 29:434–440. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Li CH, Ding H, Shi JL, Huang B, Ding H, Lin HG, Zeng JC, Zhao Y and Luo GQ: Dihydromyricetin promotes apoptosis, suppresses proliferation and tumor necrosis factor-α-mediated nuclear factor kappa-B activation in nasopharyngeal carcinoma CNE-2 cell. J Tradit Chin Med. 41:367–375. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Guo L, Zhang H and Yan X: Protective effect of dihydromyricetin revents fatty liver through nuclear factor-κB/p53/B-cell lymphoma 2-associated X protein signaling pathways in a rat model. Mol Med Rep. 19:1638–1644. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Jing N and Li X: Retraction on ‘Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway’. Open Med (Wars). 16(1082)2021.PubMed/NCBI View Article : Google Scholar | |
|
Liu M, Guo H, Li Z, Zhang C, Zhang X, Cui Q and Tian J: Molecular level insight into the benefit of myricetin and dihydromyricetin uptake in patients with Alzheimer's diseases. Front Aging Neurosci. 12(601603)2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhu H, Luo P, Fu Y, Wang J, Dai J, Shao J, Yang X, Chang L, Weng Q, Yang B and He Q: Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin. Oncotarget. 6:3254–3267. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wang Y, Wang J, Xiang H, Ding P, Wu T and Ji G: Recent update on application of dihydromyricetin in metabolic related diseases. Biomed Pharmacother. 148(112771)2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhang J, Chen Y, Luo H, Sun L, Xu M, Yu J, Zhou Q, Meng G and Yang S: Recent update on the pharmacological effects and mechanisms of dihydromyricetin. Front Pharmacol. 9(1204)2018.PubMed/NCBI View Article : Google Scholar | |
|
Huang H, Hu M, Zhao R, Li P and Li M: Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway. Oncol Rep. 30:2467–2475. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu C, Zhao P, Yang Y, Xu X, Wang L and Li B: Ampelopsin suppresses TNF-α-induced migration and invasion of U2OS osteosarcoma cells. Mol Med Rep. 13:4729–4736. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Fan TF, Wu TF, Bu LL, Ma SR, Li YC, Mao L, Sun ZJ and Zhang WF: Dihydromyricetin promotes autophagy and apoptosis through ROS-STAT3 signaling in head and neck squamous cell carcinoma. Oncotarget. 7:59691–59703. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Martínez-Alonso D and Malumbres M: Mammalian cell cycle cyclins. Semin Cell Dev Biol. 107:28–35. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Tokunaga Y, Otsuyama KI and Hayashida N: Cell cycle regulation by heat shock transcription factors. Cells. 11(203)2022.PubMed/NCBI View Article : Google Scholar | |
|
Gonzales AJ, Goldsworthy TL and Fox TR: Chemical transformation of mouse liver cells results in altered cyclin D-CDK protein complexes. Carcinogenesis. 19:1093–1102. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, Zheng Q and Cai C: CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 11:1913–1935. 2021.PubMed/NCBI | |
|
Wood DJ and Endicott JA: Structural insights into the functional diversity of the CDK-cyclin family. Open Biol. 8(180112)2018.PubMed/NCBI View Article : Google Scholar | |
|
Riba A, Oravecz A, Durik M, Jiménez S, Alunni V, Cerciat M, Jung M, Keime C, Keyes WM and Molina N: Cell cycle gene regulation dynamics revealed by RNA velocity and deep-learning. Nat Commun. 13(2865)2022.PubMed/NCBI View Article : Google Scholar | |
|
Lee JH and Berger JM: Cell Cycle-Dependent control and roles of DNA Topoisomerase II. Genes (Basel). 10(859)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zeng G, Liu J, Chen H, Liu B, Zhang Q, Li M and Zhu R: Dihydromyricetin induces cell cycle arrest and apoptosis in melanoma SK-MEL-28 cells. Oncol Rep. 31:2713–2719. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Z, Yin JQ, Wu MS, Song G, Xie XB, Zou C, Tang Q, Wu Y, Lu J, Wang Y, et al: Dihydromyricetin activates AMP-activated protein kinase and P38(MAPK) exerting antitumor potential in osteosarcoma. Cancer Prev Res (Phila). 7:927–938. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Fan KJ, Yang B, Liu Y, Tian XD and Wang B: Inhibition of human lung cancer proliferation through targeting stromal fibroblasts by dihydromyricetin. Mol Med Rep. 16:9758–9762. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Liu J, Shu Y, Zhang Q, Liu B, Xia J, Qiu M, Miao H, Li M and Zhu R: Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. Oncol Lett. 8:1645–1651. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Ni F, Gong Y, Li L, Abdolmaleky HM and Zhou JR: Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLoS One. 7(e38802)2012.PubMed/NCBI View Article : Google Scholar | |
|
Wang S, Ge F, Cai T, Qi S and Qi Z: Dihydromyricetin inhibits proliferation and migration of gastric cancer cells through regulating Akt/STAT3 signaling pathways and HMGB1 expression. Nan Fang Yi Ke Da Xue Xue Bao. 41:87–92. 2021.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Li X, Yang ZS, Cai WW, Deng Y, Chen L and Tan SL: Dihydromyricetin inhibits tumor growth and epithelial-mesenchymal transition through regulating miR-455-3p in Cholangiocarcinoma. J Cancer. 12:6058–6070. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lobe C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, Izquierdo L, Pellat A, Guedj N, Louis C, Paradis V, Banales JM, et al: Zinc Finger E-Box Binding Homeobox 1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling. Hepatology. 74:3194–3212. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Xu X, Lai Y and Hua ZC: Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Biosci Rep. 39(BSR20180992)2019.PubMed/NCBI View Article : Google Scholar | |
|
Morana O, Wood W and Gregory CD: The apoptosis paradox in cancer. Int J Mol Sci. 23(1328)2022.PubMed/NCBI View Article : Google Scholar | |
|
Cheng X and Ferrell JE Jr: Apoptosis propagates through the cytoplasm as trigger waves. Science. 361:607–612. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A and Grant S: Cotargeting BCL-2 and PI3K Induces BAX-Dependent mitochondrial apoptosis in AML cells. Cancer Res. 78:3075–3086. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zuo Y, Xu Q, Lu Y, Sun D, Wang K, Lei Y, Liang X and Li Y: Dihydromyricetin induces apoptosis in a human choriocarcinoma cell line. Oncol Lett. 16:4229–4234. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chipuk JE, McStay GP, Bharti A, Kuwana T, Clarke CJ, Siskind LJ, Obeid LM and Green DR: Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell. 148:988–1000. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ji FJ, Tian XF, Liu XW, Fu LB, Wu YY, Fang XD and Jin HY: Dihydromyricetin induces cell apoptosis via a p53-related pathway in AGS human gastric cancer cells. Genet Mol Res. 14:15564–15571. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Han JM, Kim HL and Jung HJ: Ampelopsin inhibits cell proliferation and induces apoptosis in HL60 and K562 leukemia cells by downregulating AKT and NF-κB signaling pathways. Int J Mol Sci. 22(4265)2021.PubMed/NCBI View Article : Google Scholar | |
|
Chang H, Peng X, Bai Q, Zhou Y, Yu X, Zhang Q, Zhu J and Mi M: Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway. Carcinogenesis. 35:1847–1854. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Lu CJ, He YF, Yuan WZ, Xiang LJ, Zhang J, Liang YR, Duan J, He YH and Li MY: Dihydromyricetin-mediated inhibition of the Notch1 pathway induces apoptosis in QGY7701 and HepG2 hepatoma cells. World J Gastroenterol. 23:6242–6251. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ye L, Yin G, Jiang M, Tu B, Li Z and Wang Y: Dihydromyricetin exhibits antitumor activity in nasopharyngeal cancer cell through antagonizing Wnt/β-catenin signaling. Integr Cancer Ther. 20(1534735421991217)2021.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Q, Wang J, Zhang H and Zeng T: Dihydromyricetin inhibits oxidative stress and apoptosis in oxygen and glucose deprivation/reoxygenation-induced HT22 cells by activating the Nrf2/HO-1 pathway. Mol Med Rep. 23(397)2021.PubMed/NCBI View Article : Google Scholar | |
|
Park GB, Jeong JY and Kim D: Ampelopsin-induced reactive oxygen species enhance the apoptosis of colon cancer cells by activating endoplasmic reticulum stress-mediated AMPK/MAPK/XAF1 signaling. Oncol Lett. 14:7947–7956. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Trepat X, Chen Z and Jacobson K: Cell migration. Compr Physiol. 2:2369–2392. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zanotelli MR, Zhang J and Reinhart-King CA: Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell Metab. 33:1307–1321. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chen C, Xie L, Ren T, Huang Y, Xu J and Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chou CH, Lu KH, Yang JS, Hsieh YH, Lin CW and Yang SF: Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-κB-modulated urokinase plasminogen activator inhibition. Phytomedicine. 90(153642)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang K, Yang SF, Hsieh YH, Chang YY, Yu NY, Lin HW and Lin HY: Effects of dihydromyricetin on ARPE-19 cell migration through regulating matrix metalloproteinase-2 expression. Environ Toxicol. 33:1298–1303. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zhang QY, Li R, Zeng GF, Liu B, Liu J, Shu Y, Liu ZK, Qiu ZD, Wang DJ, Miao HL, et al: Dihydromyricetin inhibits migration and invasion of hepatoma cells through regulation of MMP-9 expression. World J Gastroenterol. 20:10082–10093. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Liu T, Liu P, Ding F, Yu N, Li S, Wang S, Zhang X, Sun X, Chen Y, Wang F, et al: Ampelopsin reduces the migration and invasion of ovarian cancer cells via inhibition of epithelial-to-mesenchymal transition. Oncol Rep. 33:861–867. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wang FJ, Zong XY, DU JL, Wang WS, Yuan DP and Chen XB: [Effects of dihydromyricetin on the migration and invasion of human gastric cancer MKN45 cells and its mechanism]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 35:428–432. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Zheng HQ and Liu DY: Anti-invasive and anti-metastatic effect of ampelopsin on melanoma. Ai Zheng. 22:363–367. 2003.PubMed/NCBIIn Chinese. | |
|
Huang CC, Su CW, Wang PH, Lu YT, Ho YT, Yang SF, Hsin CH and Lin CW: Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases-2 expression in human nasopharyngeal carcinoma through extracellular signal-regulated kinase signaling pathway. Environ Toxicol. 37:1244–1253. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Chen L, Yang ZS, Zhou YZ, Deng Y, Jiang P and Tan SL: Dihydromyricetin inhibits cell proliferation, migration, invasion and promotes apoptosis via regulating miR-21 in human cholangiocarcinoma cells. J Cancer. 11:5689–5699. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sahoo BM, Banik BK, Borah P and Jain A: Reactive oxygen species (ROS): Key components in cancer therapies. Anticancer Agents Med Chem. 22:215–222. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Villalpando-Rodriguez GE and Gibson SB: Reactive oxygen species (ROS) Regulates different types of cell death by acting as a rheostat. Oxid Med Cell Longev. 2021(9912436)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D and Kutlu O: Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci. 134:116–137. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Feng Y, He D, Yao Z and Klionsky DJ: The machinery of macroautophagy. Cell Res. 24:24–41. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Onorati AV, Dyczynski M, Ojha R and Amaravadi RK: Targeting autophagy in cancer. Cancer. 124:3307–3318. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zhou Y, Shu F, Liang X, Chang H, Shi L, Peng X, Zhu J and Mi M: Ampelopsin induces cell growth inhibition and apoptosis in breast cancer cells through ROS generation and endoplasmic reticulum stress pathway. PLoS One. 9(e89021)2014.PubMed/NCBI View Article : Google Scholar | |
|
Zhou DZ, Sun HY, Yue JQ, Peng Y, Chen YM and Zhong ZJ: Dihydromyricetin induces apoptosis and cytoprotective autophagy through ROS-NF-κB signalling in human melanoma cells. Free Radic Res. 51:517–528. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Liu B, Tan X, Liang J, Wu S, Liu J, Zhang Q and Zhu R: A reduction in reactive oxygen species contributes to dihydromyricetin-induced apoptosis in human hepatocellular carcinoma cells. Sci Rep. 4(7041)2014.PubMed/NCBI View Article : Google Scholar | |
|
Qi S, Xin Y, Guo Y, Diao Y, Kou X, Luo L and Yin Z: Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways. Int Immunopharmacol. 12:278–287. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Tan M, Jiang B, Wang H, Ouyang W, Chen X, Wang T, Dong D, Yi S, Yi J, Huang Y, et al: Dihydromyricetin induced lncRNA MALAT1-TFEB-dependent autophagic cell death in cutaneous squamous cell carcinoma. J Cancer. 10:4245–4255. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tuli HS, Mistry H, Kaur G, Aggarwal D, Garg VK, Mittal S, Yerer MB, Sak K and Khan MA: Gallic Acid: A dietary polyphenol that exhibits anti-neoplastic activities by modulating multiple oncogenic targets. Anticancer Agents Med Chem. 22:499–514. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Tuli HS, Kashyap D, Sharma AK and Sandhu SS: Molecular aspects of melatonin (MLT)-mediated therapeutic effects. Life Sci. 135:147–157. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Manu KA, Shanmugam MK, Ramachandran L, Li F, Siveen KS, Chinnathambi A, Zayed ME, Alharbi SA, Arfuso F, Kumar AP, et al: Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer. Cancer Lett. 363:28–36. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Manu KA, Shanmugam MK, Li F, Chen L, Siveen KS, Ahn KS, Kumar AP and Sethi G: Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med (Berl). 92:267–276. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Jiang L, Zhang Q, Ren H, Ma S, Lu C, Liu B, Liu J, Liang J, Li M and Zhu R: Dihydromyricetin enhances the chemo-sensitivity of nedaplatin via regulation of the p53/Bcl-2 pathway in hepatocellular carcinoma cells. PLoS One. 10(e0124994)2015.PubMed/NCBI View Article : Google Scholar | |
|
He MH, Zhang Q, Shu G, Lin JC, Zhao L, Liang XX, Yin L, Shi F, Fu HL and Yuan ZX: Dihydromyricetin sensitizes human acute myeloid leukemia cells to retinoic acid-induced myeloid differentiation by activating STAT1. Biochem Biophys Res Commun. 495:1702–1707. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wang Z, Sun X, Feng Y, Liu X, Zhou L, Sui H, Ji Q, E Q, Chen J, Wu L and Li Q: Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells. Anticancer Drugs. 28:281–288. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Wang Z, Sun X, Feng Y, Wang Y, Zhang L, Wang Y, Fang Z, Azami NLB, Sun M and Li Q: Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell. Phytomedicine. 82(153414)2021.PubMed/NCBI View Article : Google Scholar | |
|
Zhu XH, Lang HD, Wang XL, Hui SC, Zhou M, Kang C, Yi L, Mi MT and Zhang Y: Synergy between dihydromyricetin intervention and irinotecan chemotherapy delays the progression of colon cancer in mouse models. Food Funct. 10:2040–2049. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xu Y, Wang S, Chan HF, Lu H, Lin Z, He C and Chen M: Dihydromyricetin induces apoptosis and reverses drug resistance in ovarian cancer cells by p53-mediated Downregulation of Survivin. Sci Rep. 7(46060)2017.PubMed/NCBI View Article : Google Scholar | |
|
Wu M, Jiang M, Dong T, Xu L, Lv J, Xue M and Huang M: Reversal effect of dihydromyricetin on multiple drug resistance in SGC7901/5-FU cells. Asian Pac J Cancer Prev. 21:1269–1274. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Dong S, Ji J, Hu L and Wang H: Dihydromyricetin alleviates acetaminophen-induced liver injury via the regulation of transformation, lipid homeostasis, cell death and regeneration. Life Sci. 227:20–29. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xiang D, Wang CG, Wang WQ, Shi CY, Xiong W, Wang MD and Fang JG: Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: An in vitro investigation. Int J Food Sci Nutr. 68:704–711. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Tong Q, Hou X, Fang J, Wang W, Xiong W, Liu X, Xie X and Shi C: Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. J Pharm Biomed Anal. 114:455–461. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Zhang R, Zhang H, Shi H, Zhang D, Zhang Z and Liu H: Strategic developments in the drug delivery of natural product dihydromyricetin: Applications, prospects, and challenges. Drug Deliv. 29:3052–3070. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Chen S, Zhao X, Wan J, Ran L, Qin Y, Wang X, Gao Y, Shu F, Zhang Y, Liu P, et al: Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacol Res. 99:74–81. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ran L, Wang X, Lang H, Xu J, Wang J, Liu H, Mi M and Qin Y: Ampelopsis grossedentata supplementation effectively ameliorates the glycemic control in patients with type 2 diabetes mellitus. Eur J Clin Nutr. 73:776–782. 2019.PubMed/NCBI View Article : Google Scholar |
